Pharmaceutical Rsrch & Mfrs of America
Pharmaceutical Research and Manufacturers of America (PhRMA), founded in 1958, is a trade group representing the pharmaceutical research and biotechnology companies in the United States. PhRMA's stated mission is advocacy for public policies that encourage the discovery of new medicines for patients by pharmaceutical and biotechnology research companies. PhRMA's current CEO is John J. Castellani.
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Pharmaceutical Rsrch & Mfrs of America
Names of Lobbyists
Firm Hired Amount Pharmaceutical Rsrch & Mfrs of America $37,200,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Science & Technology,
- Economics & Econ Development
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 S.23 Patent Reform Act of 2011 H.R.1249 America Invents Act S.27 Preserve Access to Affordable Generics Act H.R.452 Medicare Decisions Accountability Act of 2011 S.668 Health Care Bureaucrats Elimination Act S.3187 Food and Drug Administration Safety and Innovation Act S.319 Pharmaceutical Market Access and Drug Safety Act of 2011 H.R.2190 Medicare Drug Savings Act of 2011 S.365 Budget Control Act of 2011
Recent Lobbying Contracts
Date Registrant Summary Sept. 13, 2013 Ferguson Strategies Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program; Public Law No. 111-148, the "Patiet Protection and Affordable Care Act" ; and Public Law No, 108-173, the "Medicare Prescription Drug, Improvement and Modernization Act." View registration
RegulationsMentioned in 97 dockets; Submitted to 39 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Pharmaceutical Rsrch & Mfrs of America" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 2 FDA Draft Guidance for Industry on Compliance Policy for Reporting Drug Sample Distribution Information; Availability 2012
- Toggle 1 USTR Request for Comments on Mexico’s Expression of Interest in the Proposed Trans-Pacific Partnership Trade Agreement 2011
- Toggle 1 USTR 2012 Special 301 Review 2011
- Toggle 1 ITA Request for Public Comments Concerning Regulatory Cooperation Activities that Would Help Eliminate or Reduce Unnecessary Regulatory Divergences in North America that Disrupt U.S. Exports 2011
- Toggle 1 FDA Bar Code Technologies for Drugs and Biological Products; Retrospective Review Under E.O. 13563, Request for Comments 2011
- Toggle 1 DEA Disposal of Controlled Substances 2012
- Toggle 1 FDA Biologics Price Competition and Innovation Act of 2009; Options for a User Fee Program for Biosimilar and Interchangeable Biological Product Applications for Fiscal Years 2013 through 2017; Request for Comments 2011
- Toggle 1 IRS Taxable Medical Devices 2012
- Toggle 1 USTR US-EU Regulatory Compatability 2012
- Toggle 1 FDA Establishing Timeframes for Implementation of Product Safety Labeling Changes; Request for Comments 2011
Mentions in Document Text
View all mentions data for Pharmaceutical Rsrch & Mfrs of America
- Toggle 31 CMS Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests (CMS-5060-P) 2011
- Toggle 13 FDA Agency Information Collection Activities; Proposed Collection; Comment Request; Healthcare Professional Survey of Prescription Drug Promotion 2012
- Toggle 13 FDA Section 301. Foreign Supplier Verification Program 2011
- Toggle 11 CMS Medicaid Program; Covered Outpatient Drugs (CMS-2345-P) 2012
- Toggle 7 CMS Medicare Program; Proposed Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2013 and Other Proposed Changes; Considering Changes to the Conditions of Participation for Long Term Care Facilities 2011
- Toggle 6 FDA Draft Guidance for Industry on Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product; Availability 2011
- Toggle 6 FDA Draft Guidance for Industry on Standards for Clinical Trial Imaging Endpoints; Availability 2011
- Toggle 6 FDA Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing; Request for Comments 2011
- Toggle 6 CMS Exchanges Part II--Standards Related to Essential Health Benefits; Health Insurance Issuer and Exchange Responsibilities with Respect to Actuarial Value, Quality, and Accreditation CMS-9980-P 2012
- Toggle 5 USTR 2012 Special 301 Review 2011
Advisory Committees1 person on 1 committee
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Pharmaceutical Rsrch & Mfrs of America" that sat on federal advisory committees.
- Toggle Department of Commerce 1 person on 1 committee